Source link : https://www.newshealth.biz/health-news/adjuvant-avelumab-benefits-seen-in-high-risk-tnbc/
Patients with early, triple-negative breast cancer (TNBC) and high risk of recurrence after initial therapy had significantly better 3-year overall survival (OS) when given adjuvant avelumab compared with those who were observed without further treatment, in the A-BRAVE trial. “The 30% reduction in the risk of distant metastasis, and 34% reduction in the risk of […]
Author : News Health
Publish date : 2024-07-09 09:21:25
Copyright for syndicated content belongs to the linked Source.
Categories